Research
Hormonal
Both semaglutide and tirzepatide show gastrointestinal side effects including nausea, vomiting, pancreatitis, and diarrhea.
Clinicians should be aware of these common gastrointestinal side effects when prescribing these medications.
StrongSupportsmedium confidence
Both drugs showed gastrointestinal issues, including nausea, vomiting, pancreatitis, and diarrhea.
Why this rating
The review discusses post-marketing concerns, indicating a comprehensive analysis.
Source
Comparative safety and side effects of semaglutide and tirzepatide: Implications for clinical decision-making in obesity management
Sally A. Fahim et al. · Biomedicine & Pharmacotherapy · 2025
DOI 10.1016/j.biopha.2025.118731
reviewCited 4×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →